NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

Median survival of top 100 patients is 40.5 months, Median survival of all 331 patients is 23.1 months, Longest survivors have exceeded 7 years BETHESDA, Maryland, May 29, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing...

from PR Newswire: //https://ift.tt/2Ji36hB